The results still revealed that the OS of patients in the high‐risk score group is significantly lower than that in the low‐risk score group (Figure 1K), and the OS, DSS and PFI of melanoma patients with low expression of MLLT3 were poor (Figure 1L–N). This evidence concerns the gene MLLT3 and melanoma.